<DOC>
	<DOC>NCT02366026</DOC>
	<brief_summary>The primary objective is to compare &amp; evaluate between the treatment groups the changes in decline/reduction of HIV viral load changes in the Remune + Amplivax group vs the Amplivax placebo groups. Additional objectives include changes in WBC White Blood Cell counts &amp; CD4+ &amp; CD8+ T cell counts along with increased HIV immunity.</brief_summary>
	<brief_title>REMUNE + AMPLIVAX IR103 HIV/AIDS Phase III Safety &amp; Efficacy Study</brief_title>
	<detailed_description>This is a 500 subject Multi Center double-blind randomized, Safety &amp; Efficacy, HIV/AIDS Phase III study, to primarily to evaluate the safety and efficacy of HIV-1 immunogen &amp; Amplivax compared to placebo group Amplivax in viral load, and secondarily to examine changes in CD4+ &amp; CD8+ T cell counts, determine Remune vaccines effect of multiple inoculations of HIV-1 immunogen + Amplivax on viral replication in adults with HIV-1 infection &amp; to examine immunogenicity of Remune + Amplivax in a Multi-center, randomized , double-blind, placebo-controlled, two arm parallel design study of Remune + Amplivax.</detailed_description>
	<criteria>Are HIVpositive and started antiHIV drugs soon after tests showed the presence of HIV. Are at least 16 years old (consent of parent or guardian required if under 18 years). Healthy Subjects Currently abuse alcohol or drugs.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>HIV</keyword>
</DOC>